Eli Lilly and Co. (NYSE:LLY) revealed plans to inject an extra $4.5 billion into two of its Indiana manufacturing sites on Wednesday. This move escalates its total capital expansion in the state since 2020 to over $21 billion.
The additional funding is intended to support the production of Foundayo, Lilly’s newly approved weight-loss pill, and retatrutide, an obesity treatment in late-stage development.
The new investment would introduce advanced process designs and technologies at one of Lilly’s upcoming active pharmaceutical ingredient (API) facilities, as well as at its first dedicated genetic medicine manufacturing plant. The newly launched Lebanon Advanced Therapies facility would handle both clinical and commercial production of genetic medicines, supporting everything from early-stage research to large-scale commercial manufacturing.
CEO David Ricks said that Lilly’s Lebanon API facility, set to open in 2027, will become the largest API production site in U.S. history and reflects the company’s commitment to expanding manufacturing domestically. Since 2020, Lilly has committed more than $50 billion to expanding its U.S. manufacturing footprint and plans to begin construction on several newly announced facilities this year.
data-variant=”card”
data-news-mode=”manual”
>
Read Also:
Eli Lilly Advances As …
This post was originally published here
